Vijaya Diagnostic Centre Ltd sees Dr. Manjula Anagani step down as independent director
- Dr. Manjula Anagani ceased to be Independent Director on August 21, 2026
- Her five-year first term concluded without seeking re-appointment for a second term
- Cited professional commitments and pre-occupation as reasons for stepping down
- Disclosure made under Regulation 30 of SEBI Listing Regulations

*this image is generated using AI for illustrative purposes only.
Vijaya Diagnostic Centre has intimated the stock exchanges that Dr. Manjula Anagani ceased to be an Independent Director on August 21, 2026, following the completion of her tenure.
The departure marks the end of Dr. Anagani’s first term of five years on the board. The company disclosed the change under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Tenure Completion
Dr. Anagani’s role ended at the close of business hours on August 21, 2026. In a letter to the Board of Directors dated May 7, 2026, she confirmed she would not seek re-appointment for a second consecutive five-year term.
She cited pre-occupation and other professional commitments as the reasons for her decision. Dr. Anagani stated there were no other material reasons for her cessation.
Board Appreciation
The company expressed deep appreciation for the valuable services rendered by Dr. Anagani during her tenure. Naga Vasudha Tadepalli, Company Secretary and Compliance Officer, signed the disclosure letter submitted to the National Stock Exchange and BSE Limited.
Historical Stock Returns for Vijaya Diagnostic Centre
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.40% | +1.20% | +12.71% | +49.11% | +44.82% | +142.61% |
Has Vijaya Diagnostic Centre initiated a search for a new Independent Director to fill the vacancy left by Dr. Anagani?
What specific qualifications or industry experience is the board prioritizing for the successor to ensure continued regulatory compliance?
How might this leadership transition impact the company's strategic decisions regarding its upcoming expansion plans or diagnostic service offerings?


































